Browse Category

Investment Analysis News 21 December 2025

Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer Inc. (NYSE: PFE) is heading into 2026 with a familiar mix of strengths and stress fractures: a fortress-scale commercial footprint and one of Big Pharma’s deepest development machines—paired with fading COVID-era revenue, looming loss-of-exclusivity headwinds, and heightened political pressure
Netflix Stock (NFLX) News Today — Dec. 21, 2025: Warner Bros. Deal Battle, Analyst Forecasts, and What Investors Watch Next

Netflix Stock (NFLX) News Today — Dec. 21, 2025: Warner Bros. Deal Battle, Analyst Forecasts, and What Investors Watch Next

Netflix, Inc. (NASDAQ: NFLX) is ending 2025 with a rare mix of big-company stability and big-company drama: strong operating momentum, a fast-growing advertising business, and a headline-grabbing push to acquire major Warner Bros. Discovery assets—while analysts argue over whether the
Warner Bros. Discovery Stock (NASDAQ: WBD): Netflix Deal vs. Paramount Bid, Analyst Forecasts, and What Matters Next (Dec. 21, 2025)

Warner Bros. Discovery Stock (NASDAQ: WBD): Netflix Deal vs. Paramount Bid, Analyst Forecasts, and What Matters Next (Dec. 21, 2025)

Warner Bros. Discovery, Inc. stock has turned into one of the market’s most event-driven media trades heading into year-end. Instead of debating streaming churn or the next tentpole slate, investors are now weighing deal certainty, regulatory timelines, and the fine
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Latest News, Analyst Forecasts, and What Comes Next (Dec. 21, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Latest News, Analyst Forecasts, and What Comes Next (Dec. 21, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (Nasdaq: FOLD) has effectively become a “deal stock” — the market is now trading the shares primarily on the odds and timing of a takeover rather than on classic biotech catalysts.
1 67 68 69 70 71 229
Go toTop